Miklos Lipcsey
Overview
Explore the profile of Miklos Lipcsey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
1828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stattin K, Eriksson M, Frithiof R, Kawati R, Crockett D, Hultstrom M, et al.
Sci Rep
. 2025 Mar;
15(1):7333.
PMID: 40025055
The aim of this study is to investigate the association between alcohol consumption and the risk of bacterial infection and its dose-response association. Participants in the Swedish Mammography Cohort and...
2.
Plasma expansion and renal perfusion in critical COVID-19 with AKI: A prospective case control study
Luther T, Eckerbom P, Cox E, Lipcsey M, Bulow-Anderberg S, Hultstrom M, et al.
Acta Anaesthesiol Scand
. 2025 Feb;
69(3):e70004.
PMID: 39988995
Introduction: A decrease in renal perfusion during acute kidney injury (AKI) due to critical COVID-19 has previously been demonstrated. The objective of this study was to compare the effects of...
3.
Wilske F, Eriksson O, Amini R, Estrada S, Janols H, Khalil A, et al.
Intensive Care Med Exp
. 2025 Feb;
13(1):14.
PMID: 39904820
Background: Neutrophil granulocytes are important parts of the defence against bacterial infections. Their action is a two-edged sword, the mediators killing the intruding bacteria are at the same time causing...
4.
Smekal A, Swartling M, Furebring M, Giske C, Jonsson S, Lipcsey M, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):876-884.
PMID: 39847494
Objectives: This study aimed to predict the impact of different infusion strategies on pharmacokinetic/pharmacodynamic (PK/PD) target attainment and the potential risk for toxicity in an ICU cohort treated with β-lactams....
5.
6.
Aronsson Dannewitz A, Svennblad B, Michaelsson K, Lipcsey M, Gedeborg R
Crit Care
. 2024 Nov;
28(1):368.
PMID: 39543756
Background: Understanding how preexisting comorbidities may interact with a critical illness is important for the assessment of long-term survival probability of older patients admitted to the ICU. Material And Methods:...
7.
Karlsson P, Bolin C, Spang L, Frithiof R, Hultstrom M, Lipcsey M, et al.
Infect Dis (Lond)
. 2024 Nov;
57(3):284-293.
PMID: 39509144
Background: Urinary tract infections (UTIs) are prevalent among patients carrying indwelling catheters in the intensive care unit (ICU). This study investigates antibiotic use and bacterial colonisation among ICU patients during...
8.
Svedmyr A, Hedov J, Lipcsey M, Wallin M, Hallback M, Lonnqvist P, et al.
Sci Rep
. 2024 Nov;
14(1):26807.
PMID: 39500994
Sepsis continues to be a major cause of death and illness globally, posing significant challenges for healthcare professionals. In the pursuit of more accurate and timely monitoring tools, the concept...
9.
Ballgren F, Bergfast T, Ginosyan A, Mahajan J, Lipcsey M, Hammarlund-Udenaes M, et al.
Fluids Barriers CNS
. 2024 Oct;
21(1):86.
PMID: 39443944
Background: The primary objective of this study was to advance our understanding of active drug uptake at brain barriers in higher species than rodents, by examining oxycodone brain concentrations in...
10.
Bulow Anderberg S, Huckriede J, Hultstrom M, Larsson A, de Vries F, Lipcsey M, et al.
Intensive Care Med Exp
. 2024 Sep;
12(1):85.
PMID: 39340756
Background: Acute kidney injury (AKI) is common in critical cases of coronavirus disease 2019 (COVID-19) and associated with worse outcome. Dysregulated neutrophil extracellular trap (NET) formation is one of several...